2024-05-20 05:29:17 ET
Summary
- Amphastar Pharmaceuticals is a small-cap pharmaceutical company focused on developing and selling injectable, inhalation, and intranasal products.
- The company reported a 29% increase in net revenues in 2023, driven by sales growth in glucagon, Primatene MIST, epinephrine, and lidocaine.
- The recent acquisition of BAQSIMI and approval of Rextovy will further expand Amphastar's product portfolio.
This is my first article on Amphastar Pharmaceuticals ( AMPH ), a diversified pharmaceutical company. Its company profile as shown on its website bills itself as focusing on:
...developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company’s finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers.
Read the full article on Seeking Alpha
For further details see:
Amphastar Pharmaceuticals: Profitable Pharma With Strong Growth